Avizafone

Summary

Avizafone (Pro-diazepam) is a dipeptide prodrug of diazepam developed to provide a water-soluble, injectable alternative for rapid delivery of diazepam, particularly in emergency anticonvulsant and nerve agent antidote applications. It has been investigated by military and emergency medicine contexts for treatment of organophosphate poisoning and seizure emergencies.

Mechanism of Action

Avizafone is a water-soluble prodrug of diazepam. After administration, it is rapidly hydrolyzed by plasma peptidases to release diazepam, which acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory GABAergic neurotransmission to produce anxiolytic, anticonvulsant, sedative, and muscle relaxant effects.

Routes of Administration

Goals & Uses

• Seizure control in organophosphate/nerve agent poisoningEmergency Medicine / Military MedicineModerate
• Anxiolysis / SedationAnesthesia / PsychiatryLow
• Status epilepticus managementNeurology / Emergency MedicineModerate

Contraindications

• Severe respiratory depressionRespiratoryHigh
• Severe hepatic impairmentOrganModerateLiver function concerns
• Hypersensitivity to benzodiazepines or avizafone componentsAllergyHigh
• Acute narrow-angle glaucomaOphthalmologyModerate
• Myasthenia gravisNeuromuscular DiseaseHigh

Adverse Effects

• Injection site reactionsLocalUncommon
• HypotensionCardiovascularUncommonLow blood pressure
• Anterograde amnesiaNeurologicalCommon
• Respiratory depressionRespiratoryUncommon
• Dependence / Withdrawal on prolonged usePsychiatricUncommon
• CNS depression / SedationNeurologicalCommon

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)Moderate
• Other CNS depressants (barbiturates, antipsychotics, antihistamines)Moderate
• Alcohol (ethanol)High
• OpioidsHigh

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Neonates and infantsPediatricRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionInvestigationalHas been used in French military medicine; not formally approved by EMA for civilian indications.
• United StatesInvestigationalNot FDA-approved; investigated in preclinical and early clinical contexts for nerve agent antidote use.
• United KingdomInvestigationalInvestigated for military and emergency anticonvulsant use; not listed as a standard approved medicinal product by MHRA.

Avizafone is not broadly approved for civilian clinical use by major regulatory agencies such as the FDA or EMA. It has been used or investigated in military medical contexts, particularly in France and the UK, as an injectable anticonvulsant for nerve agent casualties. Regulatory status varies by jurisdiction.

Evidence & Sources

No sources recorded yet.